Pipeline news

• binx health Appoints Healthcare Industry Veteran Gail Marcus to Board of Directors

  11 June 2019

  

  binx health, the pioneer in anywhere care in women's health, today announced the appointment of Dr. Gail Marcus to its Board of Directors. Dr. Marcus is an experienced and respected healthcare leader, having held executive positions in multiple healthcare sectors including services, diagnostics, healthcare provision and managed care.  Dr. Marcus brings an in-depth understanding of the U.S. healthcare reimbursement environment, as well as strong financial and operational leadership experience to the binx board of directors.

• Adastra Pharmaceuticals Announces Positive Interim Data from Phase 1b Clinical Trial of Zotiraciclib in the Treatment of Recurrent Malignant Gliomas

  03 June 2019

  

  Adastra Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of proprietary medicines for the treatment of cancer, today announced interim data from a Phase 1b trial of the company's lead clinical candidate, zotiraciclib (TG02), in combination with temozolomide (TMZ) for the treatment of recurrent malignant gliomas.  The data, which were the subject of a poster presentation at the 2019 ASCO Annual Meeting, identified the optimal dose for zotiraciclib (250mg) in combination with TMZ, with tumor reduction indicating activity and warranting continued investigation.  

• Published Study Demonstrates Feasibility of a Blood Test to Predict Disease Progression and Metastasis in Localized Prostate Cancer

  30 May 2019

  

  Epic Sciences, Inc. announced today the publication of a six-year study demonstrating the clinical applicability of circulating tumor cells (CTCs) to predict prostate cancer progression and metastasis. The study, conducted in collaboration with the University of Michigan utilizing Epic's CTC technology platform, is published in the Journal of Clinical Oncology Precision Oncology.

• Epic Sciences Appoints New Chief Technology Officer

  22 May 2019

  

  Epic Sciences, Inc. today announced that it has named Chockalingam "Palani" Palaniappan as its new chief technology officer (CTO) to help the company advance its Functional Cell Profiling technology to drive global expansion. In his new role, Dr. Palaniappan will lead the vision for building a globally deployable, regulated platform for routine use of clinical applications for a range of cancer indications, as well as enabling drug discovery in biopharmaceutical industries.

• Slone Partners Recruits Chief Medical Officer for Epic Sciences

  21 May 2019

  

  Executive search firm Slone Partners has placed Richard Wenstrup as the chief medical officer of Epic Sciences. “Dr. Wenstrup’s decades-long experience in oncology leadership and clinical work will add substantial value to Epic Sciences in developing exciting new diagnostic tests that advance the mission of precision medicine,” said Tara Kochis-Stach, president of Slone Partners.

• Adastra Pharmaceuticals Announces that Data from Phase 1b Clinical Trial of Zotiraciclib Will Be Presented at ASCO 2019

  17 May 2019

  

  Adastra Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of proprietary medicines for the treatment of cancer, today announced that data from a Phase 1b trial of the company's lead clinical candidate, zotiraciclib (TG02), will be the subject of a poster presentation at the 2019 ASCO Annual Meeting being held in Chicago May 31 to June 4, 2019.

• Clearside Biomedical Announces First Quarter 2019 Financial Results and Provides Corporate Update

  15 May 2019

  

  Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today reported financial results for the first quarter of 2019 and provided a corporate update.

• binx health Receives CE Mark for Rapid Chlamydia and Gonorrhea Test for Mass Markets

  15 May 2019

  

  binx health, the pioneer in anywhere care today announced that its proprietary Chlamydia and Gonorrhea (CT/NG) test has received European CE Mark approval. The new multiplex test works with the binx io platform, delivering a laboratory-quality result in about 30 minutes, creating a new model for “test-and-treat” care for two of the most prevalent Sexually Transmitted Infections (STIs) globally.

• Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update

  06 May 2019

  

  Syndax Pharmaceuticals, Inc.  (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended  March 31, 2019 . In addition, the Company provided a clinical and business update. As of  March 31, 2019 , Syndax had  $92.7 million  in cash, cash equivalents and short-term investments.

• Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results

  01 May 2019

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the first quarter ended March 31, 2019.